Whole-genome plasma DNA sequencing in CRC patients under anti-EGFR therapy

Dataset ID Technology Samples
EGAD00001000748 Illumina MiSeq 19

Dataset Description

In this study we performed whole genome sequencing of plasma DNA (plasma-Seq) of 19 plasma-DNA samples from a total of 10 patients treated with anti-EGFR therapy. We demonstrated that development of resistance to anti-EGFR therapies is frequently associated with focal amplifications of KRAS, MET, and ERBB2. We also showed that focal KRAS amplifications can be acquired in tumor genomes of patients under cytotoxic chemotherapy. Furthermore, we provide evidence that specific chromosomal polysomies, such as overrepresentations of 12p and 7p, harboring KRAS and EGFR, respectively, determine responsiveness to anti-EGFR therapy.

Data Use Conditions


See further information on Data Use Conditions

Label Code Version Modifier
disease specific research DUO:0000007 2019-01-07 MONDO:0005575